NSAIDs not associated with more severe coronavirus disease, study finds


Date:
September 8, 2020
Source:
PLOS
Summary:
The use of non-steroidal anti-inflammatory drugs (NSAIDs), such
as ibuprofen and diclofenac, is not associated with any adverse
effects in people who have tested positive for COVID-19, according
to a new study.



FULL STORY ==========================================================================
The use of non-steroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen and diclofenac, is not associated with any adverse effects
in people who have tested positive for COVID-19, according to a new
study published September 8 in PLOS Medicine by Anton Pottegaard of the University of Southern Denmark and colleagues from Aarhus University
Hospital and the Danish Medicines Agency.


========================================================================== During the early phases of the COVID-19 pandemic, concerns were raised
that the use of the painkiller ibuprofen may lead to a more severe
course of coronavirus disease. As use of ibuprofen and other NSAIDs is widespread, data on their safety is urgently needed to guide clinicians
and patients. In the new study, researchers obtained data on all 9,326
Danish residents who tested positive for the SARS-CoV-2 virus between
February 27, 2020 and April 29, 2020. Data were available on NSAID use,
30-day mortality, hospitalization, ICU admission, mechanical ventilation,
and acute renal replacement therapy. 248 people (2.7%) had filled a prescription for NSAIDs within 30 days of their positive virus test.

The researchers found no association between any of the outcomes and
NSAID use.

Among NSAID users in a matched cohort who tested positive for the
coronavirus, 6.3% (95% Confidence Interval [CI] 3.1-9.4) died, 24.5%
(95% CI 18.6-30.4) were hospitalized and 4.9% (95% CI 2.1-7.8) were
admitted to ICU. Of those who tested positive for the coronavirus but
were not treated with NSAIDs, 6.1% (95% CI 4.4-7.8) died, 21.2% (95% CI 18.1-24.3) were hospitalized, and 4.7% (95% CI 3.2-6.2) were admitted
to ICU. None of these differences between groups were statistically
significant (mortality Risk Ratio [RR] 1.02, 95%CI 0.57-1.82, p=0.95; hospitalization RR 1.16, 95%CI 0.87-1.53, p=0.31; ICU admission RR 1.04,
95%CI 0.54-2.02, p = 0.90).

"Considering the available evidence, there is no reason to withdraw well- indicated use of NSAIDs during the SARS-CoV-2 pandemic," the authors say.

"However, the well-established adverse effects of NSAIDs, particularly
their renal, gastrointestinal, and cardiovascular effects, should always
be considered, and NSAIDs should be used in the lowest possible dose
for the shortest possible duration for all patients."

========================================================================== Story Source: Materials provided by PLOS. Note: Content may be edited
for style and length.


========================================================================== Journal Reference:
1. Lars Christian Lund, Kasper Bruun Kristensen, Mette Reilev, Steffen
Christensen, Reimar Wernich Thomsen, Christian Fynbo Christiansen,
Henrik Sto/vring, Nanna Borup Johansen, Nikolai Constantin Brun,
Jesper Hallas, Anton Pottegaard. Adverse outcomes and mortality in
users of non- steroidal anti-inflammatory drugs who tested positive
for SARS-CoV-2: A Danish nationwide cohort study. PLOS Medicine,
2020; 17 (9): e1003308 DOI: 10.1371/journal.pmed.1003308 ==========================================================================

Link to news story: https://www.sciencedaily.com/releases/2020/09/200908142940.htm

--- up 2 weeks, 1 day, 6 hours, 50 minutes
* Origin: -=> Castle Rock BBS <=- Now Husky HPT Powered! (1337:3/111)